Parenteral iron with erythropoiesis-stimulating agents for chemotherapy-induced anemia

Journal of Oncology Pharmacy Practice

Volumn 14, Issue 1, 2008, Pages 5-22

  Shord, Stacy S ^a   Hamilton Jr , J M ^a   Cuellar, Sandra ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Anemia; Cancer; Chemotherapy; Erythropoiesis stimulating agents; Iron

Indexed keywords

ANTINEOPLASTIC AGENT; CORTICOSTEROID; ERYTHROPOIETIN; FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; FERROUS FUMARATE; FERROUS GLUCONATE; FERROUS SULFATE; HEMOGLOBIN; IRON; IRON DEXTRAN; IRON SALT; METHYLPREDNISOLONE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; PLATINUM COMPLEX; RECOMBINANT ERYTHROPOIETIN; ANTIANEMIC AGENT; DRUG DERIVATIVE; IRON DERIVATIVE;

ALGORITHM; ANAPHYLAXIS; ANEMIA; ARTHRALGIA; ARTICLE; BLEEDING; BLOOD TRANSFUSION; BOLUS INJECTION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDICATION; DRUG POTENTIATION; DRUG RELEASE; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; HEMATOPOIESIS; HEMOGLOBIN BLOOD LEVEL; HEMOLYSIS; HUMAN; INFORMATION RETRIEVAL; IRON DEFICIENCY; IRON STORAGE; LOW DRUG DOSE; MEDLINE; MYALGIA; NAUSEA; NEOPLASM; NUTRITIONAL DEFICIENCY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RISK FACTOR; UNSPECIFIED SIDE EFFECT; VOMITING; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; DRUG EFFECT; ERYTHROPOIESIS; INTRAVENOUS DRUG ADMINISTRATION; REVIEW;

ANEMIA; ANTINEOPLASTIC AGENTS; DRUG THERAPY, COMBINATION; EPOETIN ALFA; ERYTHROPOIESIS; ERYTHROPOIETIN; HEMATINICS; HUMANS; INJECTIONS, INTRAVENOUS; IRON COMPOUNDS; PRACTICE GUIDELINES AS TOPIC;

EID: 42949109352     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1177/1078155207087654     Document Type: Article

References (84)

1. Knight K., Wade S., Balducci L. Prevalence and outcomes of anemia in cancer: A systematic review of the literature. The American Journal of Medicine 2004; 116: 11-26.
2. Ludwig H., Van Belle S., Barrett-Lee P. et al. The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004; 40: 2293-306.
3. National Comprehensive Cancer Network I. Cancer- and treatment-related anemia (3. 2007). http://www.nccn.org/professionals/physician_gls/PDF/ anemia.pdf. Accessed June 19, 2007.
4. Cella D. Factors influencing quality of life in cancer patients: Anemia and fatigue. Semin Oncol 1998; 25: 43-6.
5. Leitgeb C., Pecherstorfer M., Fritz E., Ludwig H. Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer 1994; 73: 2535-42.
6. Littlewood TJ, Bajetta E., Nortier JWR, Vercammen E., Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001; 19: 2865-74.
7. Razzouk BI, Hord JD, Hockenberry M. et al. Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy. J Clin Oncol 2006; 24: 3583-9.
8. Cascinu S., Fedeli A., Del Ferro E., Luzi Fedeli S., Catalano G. Recombinant human erythropoietin treatment in cisplatin-associated anemia: A randomized, double-blind trial with placebo. J Clin Oncol 1994; 12: 1058-62.
9. Case Jr DC, Bukowski RM, Carey RW et al. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy 10.1093/jnci/85.10.801. J Natl Cancer Inst 1993; 85: 801-6.
10. Henry DH, Brooks Jr BJ, Case Jr DC et al. Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy. Cancer J Sci Am 1995; 1: 252.
11. Markman M., Reichman B., Hakes T. et al. The use of recombinant human erythropoietin to prevent carboplatin-induced anemia. Gynecologic Oncology 1993; 49: 172-6.
12. Birgegard G., Osterborg A., Hedenus M. Functional iron deficiency effectively overcome by adjuvant IV iron during epoetin treatment. ASH Annual Meeting Abstracts 2006; 108: 3725.
13. Rizzo JD, Somerfield MR, Hagerty KL et al. American Society of Clinical Oncology/American Society of Hematology 2007 clinical practice guideline update on the use of epoetin and darbepoetin. J Clin Oncol 2007; Oct 22.
14. Rizzo JD, Somerfield MR, Hagerty KL et al. American Society of Hematology/American Society of Clinical Oncology 2007 clinical practice guideline update on the use of epoetin and darbepoetin. Blood 2007; Oct 23.
15. Aranesp prescribing information. Thousand Oaks, CA: Amgen, Inc., 2007.
16. Procrit prescribing information. Raritan, NJ: Ortho-Biotech, L.P., 2007.
17. Demetri GD Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy. Br J Cancer 2001; 84: 31-7.
18. Cella D. The functional assessment of cancer therapy-anemia (FACT-An) scale: A new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997; 34: 13-9.
19. Cella D., Zagari MJ, Vandoros C., Gagnon DD, Hurtz HJ, Nortier JW Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. J Clin Oncol 2003; 21: 366-73.
20. Fairclough DL, Gagnon DD, Zagari MJ, Marschner N., Dicato M. Evaluation of quality of life in a clinical trial with nonrandom dropout: The effect of epoetin alfa in anemic cancer patients. Qual Life Res 2003; 12: 1013-27.
21. Jones M., Schenkel B., Just J., Fallowfield L. Epoetin alfa improves quality of life in patients with cancer: Results of metaanalysis. Cancer 2004; 101: 1720-32.
22. Chang J., Couture F., Young S., McWatters KL, Lau CY Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol 2005; 23: 2597-605.
23. Treating anaemia with epoetin alfa is associated with improvements in quality of life in cancer patients receiving chemotherapy. Curr Med Res Opin 2005; 21: S9-11.
24. Epoetin alfa offers clinically significant improvements in the quality of life of anaemic cancer patients. Curr Med Res Opin 2005; 21: S12-5.
25. Bennett CL The blue cross blue shield assessment technology review: summary of findings. Best Practice & Research Clinical Haematology Erythropoietin Use in Oncology: A Summary of the Evidence 2005; 18: 423-31.
26. Lyman GH, Glaspy J. Are there clinical benefits with early erythropoietic intervention for chemotherapy-induced anemia? Cancer 2006; 106: 223-33.
27. Boccia R., Malik IA, Raja V. et al. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia. Oncologist 2006; 11: 409-17.
28. Crawford J., Cella D., Cleeland CS et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002; 95: 888-95.
29. Henke M., Laszig R., Rube C. et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 2003; 362: 1255-60.
30. Leyland-Jones B., Semiglazov V., Pawlicki M. et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study. J Clin Oncol 2005; 23: 5960-72.
31. Food and Drug Administration. Safety concerns associated with Aranesp (darbepoetin alfa) Amgen, Inc and Procrit (epoetin alfa) Ortho Biotech, L.P. for the treatment of anemia associated with cancer chemotherapy. http://www.fda.gov/ohrms/dockets/ac/04/briefing/4037b2_04.pdf. Oncologic Advisory Committee Briefing Document. 2004.
32. Wright JR, Ung YC, Julian JA et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007; 25: 1027-32.
33. Rizzo JD, Lichtin AE, Woolf SH et al. Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002; 20: 4083-107.
34. Rizzo JD, Lichtin AE, Woolf SH et al. Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 2002; 100: 2303-20.
35. Glaspy J., Vadhan-Raj S., Patel R. et al. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: The 20030125 Study Group Trial. J Clin Oncol 2006; 24: 2290-97.
36. Schwartzberg LS, Yee LK, Senecal FM et al. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer. Oncologist 2004; 9: 696-707.
37. Senecal FM, Yee L., Gabrail N. et al. Treatment of chemotherapy-induced anemia in breast cancer: Results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly. Clin Breast Cancer 2005; 6: 446-54.
38. Waltzman R., Croot C., Justice GR, Fesen MR, Charu V., Williams D. Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 mcg every 2 weeks) in anemic patients with cancer receiving chemotherapy. Oncologist 2005; 10: 642-50.
39. Case AS, Rocconi RP, Kilgore LC, Barnes MN Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies. Gynecol Oncol 2006; 101: 499-502.
40. Glaspy J., Moyo V., Kamin M., Wilhelm FE Early and standard intervention with epoetin alfa (PROCRIT(R)) 120,000 units (U) every three weeks (Q3W) in patients with cancer receiving chemotherapy - results of a planned interim analysis. ASH Annual Meeting Abstracts 2006; 108: 3774.
41. Shasha D., Dawkins F., Wilhelm FE Epoetin alfa 80,000 U every three weeks (Q3W) in anemic cancer patients (pts) not receiving chemotherapy (CT) or radiation therapy (RT). ASH Annual Meeting Abstracts. 2006; 108: 3755.
42. Henry D., Kamin M., Wilhelm F., Williams D., Xie J., Woodman R. Final results of a randomized study comparing two dosing regimens of epoetin alfa in patients with chemotherapy-induced anemia: 80,000 U every two weeks vs 40,000 U weekly. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I. 2006; 24: 8624.
43. Steensma DP, Molina R., Sloan JA et al. Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer. 10.1200/JCO.2005.02.7276. J Clin Oncol 2006; 24: 1079-89.
44. Herrington JD, Davidson SL, Tomita DK, Green L., Smith RE, Boccia RV Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. Am J Health Syst Pharm 2005; 62: 54-62.
45. Glaspy JA, Jadeja JS, Justice G. et al. Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer 2002; 87: 268-76.
46. Patton J., Reeves T., Wallace J. Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy-induced anemia treated in clinical practice. Oncologist 2004; 9: 451-8.
47. Vansteenkiste J., Tomita D., Rossi G., Pirker R. Darbepoetin alfa in lung cancer patients on chemotherapy: A retrospective comparison of outcomes in patients with mild versus moderate-to-severe anaemia at baseline. Support Care Cancer 2004; 12: 253-62.
48. Canon JL, Vansteenkiste J., Bodoky G. et al. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst 2006; 98: 273-84.
49. Kotasek D., Steger G., Faught W. et al. Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. Eur J Cancer 2003; 39: 2026-34.
50. Hernandez EDJ, Kotasek D., Ganly P., Silberstein P., Tomita D., Lillie T., Boccia R. Effectiveness of darbepoetin alfa 300 mcg every 3 weeks in patients with chemotherapy-induced anemia. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I 2006; 24: 18545.
51. Taylor K., Ganly P., Charu V., et al. Randomized, double-blind, placebo-controlled study of darbepoetin alfa every 3 weeks for the treatment of chemotherapy-induced anemia. ASH Annual Meeting Abstracts. November 16, 2005; 106: 3556.
52. Rearden TP, Charu V., Saidman B., Ben-Jacob A., Justice GR, Manaim AS, Tomita D., Rossi, G. Results of a randomized study of every three-week dosing (Q3W) of darbepoetin alfa for chemotherapy-induced anemia (CIA). J Clin Oncol, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2004; 22: 8064.
53. Hedenus M., Adriansson M., San Miguel J. et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: A randomized, double-blind, placebo-controlled study. Br J Haematol 2003; 122: 394-403.
54. Locatelli F., Aljama P., Barany P. et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19: 1-47.
55. Seidenfeld J., Piper M., Flamm C. et al. Epoetin treatment of anemia associated with cancer therapy: A systematic review and meta-analysis of controlled clinical trials. 10.1093/jnci/93.16.1204. J Natl Cancer Inst 2001; 93: 1204-14.
56. Granetto C., Ricci S., Martoni A. et al. Comparing the efficacy and safety of fixed versus weight-based dosing of epoetin alpha in anemic cancer patients receiving platinum-based chemotherapy. Oncol Rep 2003; 10: 1289-96.
57. Ineck B., Mason B., Thomas EG Anemia. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells B, Posey M. Pharmacotherapy: A pathophysiologic approach. 6 eds, Stanford: Appleton and Lange; 2004.
58. Henry D., Dahl NV Iron or vitamin B12 deficiency in anemic cancer patients prior to erythropoiesis-stimulating agent therapy. Community Oncology 2007; 4: 95-101.
59. KDOQI; National Kidney Foundation II. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis 2006; 47: S16-85.
60. Auerbach M., Ballard H., Trout JR et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: A multicenter, open-label, randomized trial. J Clin Oncol 2004; 22: 1301-7.
61. Henry DH, Dahl NV, Auerbach M., Tchekmedyian S., Laufman LR Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007; 12: 231-42.
62. Hedenus M., Birgegard G., Nasman P. et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: A randomized multicenter study. Leukemia 2007; 21: 627-32.
63. Bellet RE, Ghazal H., Flam M., et al. A phase III randomized controlled study comparing iron sucrose intravenously to no iron treatment of anemia in cancer patients undergoing chemotherapy and erythropoietin stimulating agent (ESA) therapy. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 2007; 25(18S (June 20 Supplement)): 9109.
64. Lerchenmueller C., Husseini F., Gaede B., Mossman T., Suto T., Vanderbroek A. Intravenous (IV) iron supplementation in patients with chemotherapy-induced anemia (CIA) receiving darbepoetin alfa every 3 weeks (Q3W): Iron parameters in a randomized controlled trial. ASH Annual Meeting Abstracts 2006; 108: 1552.
65. Chuang CL, Liu RS, Wei YH, Huang TP, Tarng DC Early prediction of response to intravenous iron supplementation by reticulocyte haemoglobin content and high-fluorescence reticulocyte count in haemodialysis patients. Nephrol Dial Transplant 2003; 18: 370-7.
66. Lee EJ, Oh E-J., Park Y-J., Lee HK, Kim BK Soluble transferrin receptor (sTfR), ferritin, and sTfR/log ferritin index in anemic patients with nonhematologic malignancy and chronic inflammation. Clin Chem 2002; 48: 1118-21.
67. Coyne DW, Kapoian T., Suki W. et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients' Response to IV Iron and Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 2007; 18: 975-84.
68. Haurani FI, Green D., Young K. Iron absorption in hypoferremia. Am J Med Sci 1965; 249: 537-47.
69. Weinstein DA, Roy CN, Fleming MD, Loda MF, Wolfsdorf JI, Andrews NC Inappropriate expression of hepcidin is associated with iron refractory anemia: Implications for the anemia of chronic disease. Blood 2002; 100: 3776-81.
70. Nemeth E., Tuttle MS, Powelson J. et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004; 306: 2090-3.
71. Andrews NC Anemia of inflammation: The cytokinehepcidin link. J Clin Invest 2004; 113: 1251-3.
72. Savonije JH, van Groeningen CJ, van den Broek WJ et al. Iron absorption during epoetin alfa therapy for chemotherapy-associated anaemia. Cancer Invest 2006; 24: 562-6.
73. Dexferrum prescribing information. Shirley, NY: American Reagents Laboratories, Inc., 2001.
74. InFed prescribing information. Morristown, NJ: Watson Pharma, Inc., 2001.
75. Ferrlicet prescribing information. Morristown, NJ: Watson Pharma, Inc., 2004.
76. Venofer prescribing Information. Shirley, NY: American Reagent Laboratories, Inc., 2005.
77. Weinberg ED The role of iron in cancer. Eur J Cancer Prev 1996; 5: 19-36.
78. Coyne DW, Adkinson NF, Nissenson AR, et al. Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients. Kidney Int 2003; 63: 217-24.
79. McCarthy JT, Regnier CE, Loebertmann CL, Bergstralh EJ Adverse events in chronic hemodialysis patients receiving intravenous iron dextran-a comparison of two products. Am J Nephrol 2000; 20: 455-62.
80. Chertow GM, Mason PD, Vaage-Nilsen O., Ahlmen J. On the relative safety of parenteral iron formulations. Nephrol Dial Transplant 2004; 19: 1571-5.
81. Chertow GM, Mason PD, Vaage-Nilsen O., Ahlmen J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006; 21: 378-82.
82. Auerbach M., Chaudhry M., Goldman H., Ballard H. Value of methylprednisolone in prevention of the arthralgiamyalgia syndrome associated with the total dose infusion of iron dextran: A double blind randomized trial. J Lab Clin Med 1998; 131: 257-60.
83. Auerbach M., Henry DH Increased importance of intravenous iron in chemotherapy-induced anemia. J Clin Oncol 2007; 25: 2145-6.
84. Lalle M., Pistillucci G., Antimi M., D'Aprile M. Epoetin alfa 40000 U once weekly and intravenous iron supply in solid tumor patients: Early increase of hemoglobin level during chemotherapy. J Exp Clin Cancer Res. 2005; 24: 197-201.